BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bell JC, Rose DN, Sacks HS. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. AIDS. 1999;13:1549-1556. [PMID: 10465080 DOI: 10.1097/00002030-199908200-00016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Gayle HD, Hill GL. Global impact of human immunodeficiency virus and AIDS. Clin Microbiol Rev 2001;14:327-35. [PMID: 11292641 DOI: 10.1128/CMR.14.2.327-335.2001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
2 Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002;359:1635-43. [PMID: 12020523 DOI: 10.1016/S0140-6736(02)08595-1] [Cited by in Crossref: 211] [Cited by in F6Publishing: 82] [Article Influence: 11.1] [Reference Citation Analysis]
3 Zaeh S, Kempker R, Stenehjem E, Blumberg HM, Temesgen O, Ofotokun I, Tenna A. Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. Int J Tuberc Lung Dis 2013;17:1396-401. [PMID: 24125440 DOI: 10.5588/ijtld.13.0315] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
4 Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, Toure S, Smith HE, Kaplan JE, Freedberg KA; Global AIDS Policy Model Investigators. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS 2005;19:1299-308. [PMID: 16052085 DOI: 10.1097/01.aids.0000180101.80888.c6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 4.0] [Reference Citation Analysis]
5 Kahn JG, Marseille E, Auvert B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med 2006;3:e517. [PMID: 17194197 DOI: 10.1371/journal.pmed.0030517] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 7.9] [Reference Citation Analysis]
6 Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, Scott CA, Mayer KH, Freedberg KA, Walensky RP. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012;7:e36001. [PMID: 22558301 DOI: 10.1371/journal.pone.0036001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shayo GA, Chitama D, Moshiro C, Aboud S, Bakari M, Mugusi F. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. BMC Public Health 2017;18:35. [PMID: 28724374 DOI: 10.1186/s12889-017-4597-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
8 Nugent R, Barnabas RV, Golovaty I, Osetinsky B, Roberts DA, Bisson C, Courtney L, Patel P, Yonga G, Watkins D. Costs and cost-effectiveness of HIV/noncommunicable disease integration in Africa: from theory to practice. AIDS 2018;32 Suppl 1:S83-92. [PMID: 29952794 DOI: 10.1097/QAD.0000000000001884] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
9 Steffen RE, Pinto M, Kritski A, Trajman A. Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV. Sci Rep 2020;10:21823. [PMID: 33311520 DOI: 10.1038/s41598-020-78737-w] [Reference Citation Analysis]
10 Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, Jawe E, Were W, Mermin J. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy 2009;7:229-43. [PMID: 19905037 DOI: 10.2165/11318740-000000000-00000] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
11 Houben RM, Dowdy DW, Vassall A, Cohen T, Nicol MP, Granich RM, Shea JE, Eckhoff P, Dye C, Kimerling ME, White RG; TB MAC TB-HIV meeting participants. How can mathematical models advance tuberculosis control in high HIV prevalence settings? Int J Tuberc Lung Dis 2014;18:509-14. [PMID: 24903784 DOI: 10.5588/ijtld.13.0773] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
12 Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, Rabie H, Lombard CJ. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007;334:136. [PMID: 17085459 DOI: 10.1136/bmj.39000.486400.55] [Cited by in Crossref: 132] [Cited by in F6Publishing: 111] [Article Influence: 8.8] [Reference Citation Analysis]
13 Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, Hubben G. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med. 2011;183:1103-1111. [PMID: 21148723 DOI: 10.1164/rccm.201004-0620oc] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
14 Bortolotti V, Buvé A. Prophylaxis of opportunistic infections in HIV-infected adults in sub-Saharan Africa: opportunities and obstacles: . AIDS 2002;16:1309-17. [DOI: 10.1097/00002030-200207050-00002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
15 Floyd K. Costs and effectiveness--the impact of economic studies on TB control. Tuberculosis (Edinb) 2003;83:187-200. [PMID: 12758211 DOI: 10.1016/s1472-9792(02)00077-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rutherford ME, Hill PC, Triasih R, Sinfield R, van Crevel R, Graham SM. Preventive therapy in children exposed to Mycobacterium tuberculosis: problems and solutions. Trop Med Int Health 2012;17:1264-73. [PMID: 22862994 DOI: 10.1111/j.1365-3156.2012.03053.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
17 Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24 Suppl 5:S57-S65. [PMID: 21079430 DOI: 10.1097/01.aids.0000391023.03037.1f] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
18 Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, Jawe E, Were W, Mermin J. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy 2009;7:229-43. [DOI: 10.1007/bf03256157] [Cited by in Crossref: 29] [Article Influence: 3.2] [Reference Citation Analysis]
19 Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature. J Acquir Immune Defic Syndr 2015;68 Suppl 3:S297-305. [PMID: 25768869 DOI: 10.1097/QAI.0000000000000497] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
20 Maheswaran H, Barton P. Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis. PLoS One 2012;7:e30457. [PMID: 22291958 DOI: 10.1371/journal.pone.0030457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
21 Currie CS, Floyd K, Williams BG, Dye C. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health 2005;5:130. [PMID: 16343345 DOI: 10.1186/1471-2458-5-130] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
22 Guwatudde D, Debanne SM, Diaz M, King C, Whalen CC. A re-examination of the potential impact of preventive therapy on the public health problem of tuberculosis in contemporary sub-Saharan Africa. Prev Med 2004;39:1036-46. [PMID: 15475039 DOI: 10.1016/j.ypmed.2004.04.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
23 Hyle EP, Naidoo K, Su AE, El-Sadr WM, Freedberg KA. HIV, tuberculosis, and noncommunicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care? J Acquir Immune Defic Syndr 2014;67 Suppl 1:S87-95. [PMID: 25117965 DOI: 10.1097/QAI.0000000000000254] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
24 Reddy KP, Brady MF, Gilman RH, Coronel J, Navincopa M, Ticona E, Chavez G, Sánchez E, Rojas C, Solari L, Valencia J, Pinedo Y, Benites C, Friedland JS, Moore DA. Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. Clin Infect Dis 2010;50:988-96. [PMID: 20192727 DOI: 10.1086/651081] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
25 Uyei J, Coetzee D, Macinko J, Guttmacher S. Integrated delivery of HIV and tuberculosis services in sub-Saharan Africa: a systematic review. The Lancet Infectious Diseases 2011;11:855-67. [DOI: 10.1016/s1473-3099(11)70145-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
26 Sardar P, Jha A, Roy D, Roy S, Guha P, Bandyopadhyay D. Intensive phase non-compliance to anti tubercular treatment in patients with HIV-TB coinfection: a hospital-based cross-sectional study. J Community Health 2010;35:471-8. [PMID: 20041282 DOI: 10.1007/s10900-009-9215-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
27 Mermin J, Bunnell R, Lule J, Opio A, Gibbons A, Dybul M, Kaplan J. Developing an evidence-based, preventive care package for persons with HIV in Africa. Trop Med Int Health 2005;10:961-70. [PMID: 16185230 DOI: 10.1111/j.1365-3156.2005.01488.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
28 Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007;196 Suppl 1:S52-62. [PMID: 17624827 DOI: 10.1086/518662] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
29 Hsieh YL, Jahn A, Menzies NA, Yaesoubi R, Salomon JA, Girma B, Gunde L, Eaton JW, Auld A, Odo M, Kiyiika CN, Kalua T, Chiwandira B, Mpunga JU, Mbendra K, Corbett L, Hosseinipour MC, Cohen T, Kunkel A. Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi. J Acquir Immune Defic Syndr 2020;85:643-50. [PMID: 33177475 DOI: 10.1097/QAI.0000000000002497] [Reference Citation Analysis]
30 Cobelens FG, Egwaga SM, van Ginkel T, Muwinge H, Matee MI, Borgdorff MW. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis 2006;43:634-9. [PMID: 16886159 DOI: 10.1086/506432] [Cited by in Crossref: 65] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
31 Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, Porter JDH, Godfrey-Faussett P. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001;15:215-22. [PMID: 11216930 DOI: 10.1097/00002030-200101260-00011] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
32 Reid A, Scano F, Getahun H, Williams B, Dye C, Nunn P, De Cock KM, Hankins C, Miller B, Castro KG, Raviglione MC. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. The Lancet Infectious Diseases 2006;6:483-95. [DOI: 10.1016/s1473-3099(06)70549-7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
33 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
34 Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nat Rev Immunol 2005;5:819-26. [DOI: 10.1038/nri1704] [Cited by in Crossref: 156] [Cited by in F6Publishing: 129] [Article Influence: 9.8] [Reference Citation Analysis]
35 Umar NA, Fordham R, Abubakar I, Bachmann M. The indirect cost due to pulmonary Tuberculosis in patients receiving treatment in Bauchi State-Nigeria. Cost Eff Resour Alloc 2012;10:6. [PMID: 22577948 DOI: 10.1186/1478-7547-10-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
36 Marais BJ, Ayles H, Graham SM, Godfrey-faussett P. Screening and Preventive Therapy for Tuberculosis. Clinics in Chest Medicine 2009;30:827-46. [DOI: 10.1016/j.ccm.2009.08.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
37 Diel R, Lampenius N, Nienhaus A. Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations. PharmacoEconomics 2015;33:783-809. [DOI: 10.1007/s40273-015-0267-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]